Revolutionary Approach to Immunotherapy
Based on the individual genetic profile of the patient, the personalized cancer vaccine opens a new chapter in immunotherapy. The key to its creation is the analysis of genetic mutations present in cancer cells, enabling the selection of specific genes for each patient. Such an individual approach allows the immune system to be stimulated to target cancer cells, increasing the effectiveness of the treatment.
Optimistic Research Results
The results presented by the team at Johns Hopkins University are promising. Among patients treated with the new vaccine, nearly 31% responded positively to the treatment, which is a significant improvement compared to traditional methods. Additionally, for some patients, the study resulted in complete healing. It was also noted that the average survival time of patients who underwent therapy extended to almost 20 months. Equally important, the study did not show any serious side effects after the application of the vaccine.
Further Steps and Perspectives
Despite the optimistic results, further, broader clinical studies are necessary to fully verify the effectiveness and safety of using the personalized vaccine. Scientists emphasize that further refinement of the method will be key to making it available to a wider group of patients.
